Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology

Arthritis medications
newGeneral Health
Medicinal food
Chinese medicine
OTC Drugs
Health Products

30 FlexPenNovoMix 30 FlexPen

Suspension for injection in a pre-filled pen

Qualitative and quantitative composition

Soluble insulin aspart*/protamine-crystallised
insulin aspart* 100 U/ml in the ratio of 30/70 * produced by recombinant DNA technology in Saccharomyces cerevisiae.
One unit of insulin aspart corresponds to 6 nmol, 0.035 mg salt-free anhydrous insulin aspart.
1 pre-filled pen contains 3 ml equivalent to 300 U.

Pharmaceutical form

Suspension for injection.
NovoMix 30 is a white suspension.

Clinical particulars

Therapeutic indications

Treatment of diabetes mellitus.

Posology and method of administration

NovoMix 30 has a faster onset of action than biphasic human insulin and should generally be given immediately before a meal. When necessary, NovoMix 30 can be given soon after a meal.

Transfer to NovoMix 30 from other insulin preparations may require adjustment of dose and timing of administration. As with all insulins, close glucose monitoring is recommended during transition and the initial weeks thereafter.

NovoMix 30 is administered subcutaneously in the thigh or in the abdominal wall. If convenient, the gluteal or deltoid region may be used. Injection sites should be rotated within the same region. As with all insulins the duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity. The influence of different injection sites on the absorption of NovoMix 30 has not been investigated. NovoMix 30 should never be administered intravenously.

Renal or hepatic impairment may reduce the patient's insulin requirements.

NovoMix 30 can be used in children and adolescents aged 10 years and above when premixed insulin is preferred. For children 6-9 years limited clinical data exists.


No studies have been performed in children under the age of 6 years.

Dose recommendation:
Dosage of NovoMix 30 is individual and determined in accordance with the needs of the patient.

In patients with type 2 diabetes, NovoMix 30 can be given in monotherapy or in combination with, oral antidiabetic drugs when the blood glucose is inadequately controlled with those oral antidiabetic drugs alone. For patients with type 2 diabetes, the recommended starting dose of NovoMix 30 is 6 U at breakfast and 6 U at dinner (evening meal). NovoMix 30 can also be initiated once daily with 12 U at dinner (evening meal). When using NovoMix 30 once daily, it is generally recommended to move to twicedaily when reaching 30 units by splitting the dose into equal breakfast and dinner doses. A NovoMix 30 thricedaily regimen can be safely initiated from a twice-daily regimen by splitting the morning dose into morning and lunch doses.

The following titration guideline is recommended for dose adjustment:
Pre-meal blood glucose level NovoMix 30 dose adjustment
< 4.4 mmol/l < 80 mg/dL -2U
4.4 - 6.1 mmol/l 80 - 110 mg/dL 0
6.2 - 7.8 mmol/l 111 - 140 mg/dL +2U
7.9 - 10 mmol/l 141 - 180 mg/dL +4U
> 10 mmol/l > 180 mg/dL +6U


The lowest of three previous days' pre-meal levels should be used. The dose should not be increased if hypoglycaemia occurred within these days. Dose adjustment can be made once a week until target HbA1c, is reached. Pre-meal blood glucose levels should be used to evaluate the adequacy of the preceding dose.

In patients with type 1 diabetes the individual insulin requirement is usually between 0.5 and 1.0 Units/kg/day. NovoMix 30 may fully or partially meet this requirement. The daily insulin requirement may be higher in patients with insulin resistance (e.g due to obesity), and lower in patients with residual endogenous insulin production. NovoMix 30 can be used in elderly patients; however there is limited experience with the use of NovoMix 30 in combination with OADs in patients older than 75 years.

Hypersensitivity to the active substance or to any of the excipients

Special warnings and precautions for use
The use of dosages which are inadequate or discontinuation of treatment, especially in insulindependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis, conditions which are potentially lethal.

Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia. Compared with biphasic human insulin, NovoMix 30 may have a more pronounced glucose lowering effect up to 6 hours after injection. This may have to be compensated for in the individual patient, through adjustment of insulin dose and/or food intake.

Patients, whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly.


Tighter control of glucose levels can increase the potential for hypoglycaemic episodes and therefore require special attention during dose intensification.


NovoMix 30 should be administered in immediate relation to a meal. The rapid onset of action should therefore be considered in patients with concomitant diseases or treatment with other medicinal products where a delayed absorption of food might be expected. Concomitant illness, especially infections, usually increases the patient's insulin requirements.


When patients are transferred between different types of insulin products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.


Transferring a patient to a new type or brand of insulin should be done under strict medical supervision Changes in strength, brand (manufacturer), type, origin (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dosage.


Patients taking NovoMix 30 may need a change in dosage from that used with their usual insulins. If dosage adjustment is needed, it may be done with the first dose or during the first few weeks or months.


Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.


Insulin suspensions are not to be used in insulin infusion pumps.

As with any insulin therapy, injection site reactions may occur and include pain, itching, hives, swelling and inflammation. Continuous rotation of the injection site within a given area may help to reduce or prevent these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of NovoMix 30.

1    2    3











Health news
Cardiovascular Guide
Natural Remedies
Treatment of Cancer
Women's Health
Irritable bowel syndrome
Common Childhood Illnesses
Prescribed Drugs